His primary areas of investigation include Internal medicine, Breast cancer, Cancer research, Oncology and Cancer. His Internal medicine study frequently draws connections between related disciplines such as Endocrinology. His Breast cancer research incorporates elements of Surgery, Gastroenterology, Hazard ratio, Antibody and Adjuvant therapy.
His Cancer research study also includes
Masakazu Toi mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Cancer research. He works mostly in the field of Breast cancer, limiting it down to concerns involving Pathology and, occasionally, Mammary gland. Masakazu Toi combines topics linked to Endocrinology with his work on Internal medicine.
His Oncology research integrates issues from Taxane, Clinical trial, Phases of clinical research, Fulvestrant and Adjuvant therapy. His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Cell, Cell culture and Immunology. Masakazu Toi has included themes like Cyclophosphamide and Anthracycline in his Docetaxel study.
The scientist’s investigation covers issues in Breast cancer, Internal medicine, Oncology, Cancer and Metastatic breast cancer. His Breast cancer research incorporates themes from Interim analysis, Cancer research, Clinical endpoint, Radiology and Subgroup analysis. In his study, Aromatase inhibitor and Quality of life is inextricably linked to Placebo, which falls within the broad field of Internal medicine.
His research integrates issues of Taxane, Phases of clinical research, Neutropenia, Palbociclib and Letrozole in his study of Oncology. The Cancer study combines topics in areas such as Proportional hazards model and Cohort study. The various areas that he examines in his Metastatic breast cancer study include Progressive disease and Nivolumab.
His main research concerns Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Pertuzumab. His studies link Placebo with Internal medicine. The concepts of his Breast cancer study are interwoven with issues in Regimen, Cancer research and Randomized controlled trial.
His work deals with themes such as Cancer, Endocrine therapy, Tolerability and Chemotherapy, which intersect with Oncology. His studies examine the connections between Pertuzumab and genetics, as well as such issues in Adjuvant therapy, with regards to Placebo-controlled study and Standard of care. His studies in Trastuzumab integrate themes in fields like Taxane and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn.
Journal of Clinical Oncology (2017)
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Chikashi Nakanishi;Masakazu Toi.
Nature Reviews Cancer (2005)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im.
The New England Journal of Medicine (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn.
Journal of Clinical Oncology (2017)
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Takayuki Ueno;Masakazu Toi;Hisashi Saji;Mariko Muta.
Clinical Cancer Research (2000)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2017)
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation
P. E. Vermeulen;G. Gasparini;S. B. Fox;Masakazu Toi.
European Journal of Cancer (1996)
Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer
Masakazu Toi;Seigo Hoshina;Toshiaki Takayanagi;Takeshi Tominaga.
Japanese Journal of Cancer Research (1994)
Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
Masakazu Toi;Kazuo Inada;Hideo Suzuki;Takeshi Tominaga.
Breast Cancer Research and Treatment (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: